[go: up one dir, main page]

MX2018015363A - Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria. - Google Patents

Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.

Info

Publication number
MX2018015363A
MX2018015363A MX2018015363A MX2018015363A MX2018015363A MX 2018015363 A MX2018015363 A MX 2018015363A MX 2018015363 A MX2018015363 A MX 2018015363A MX 2018015363 A MX2018015363 A MX 2018015363A MX 2018015363 A MX2018015363 A MX 2018015363A
Authority
MX
Mexico
Prior art keywords
celiac
celiac disease
treatment
methods
refractory
Prior art date
Application number
MX2018015363A
Other languages
English (en)
Inventor
Leon Francisco
H Tsuji Wayne
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2018015363A publication Critical patent/MX2018015363A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se proveen métodos y composiciones farmacéuticas para el tratamiento de trastornos inflamatorios, en particular enfermedad celiaca, enfermedad celíaca refractaria y sensibilidad al gluten no celíaca.
MX2018015363A 2016-06-15 2016-06-15 Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria. MX2018015363A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/037708 WO2017217985A1 (en) 2016-06-15 2016-06-15 Methods and compositions for the treatment of celiac disease, non-celiac gluten sensitivity, and refractory celiac disease

Publications (1)

Publication Number Publication Date
MX2018015363A true MX2018015363A (es) 2019-04-15

Family

ID=56292925

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015363A MX2018015363A (es) 2016-06-15 2016-06-15 Metodos y composiciones para el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.
MX2024001374A MX2024001374A (es) 2016-06-15 2016-06-15 Anticuerpo anti-il-15 o fragmento de union a antigeno del mismo, para usarse en el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024001374A MX2024001374A (es) 2016-06-15 2016-06-15 Anticuerpo anti-il-15 o fragmento de union a antigeno del mismo, para usarse en el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.

Country Status (11)

Country Link
EP (1) EP3472202A1 (es)
JP (2) JP2019521981A (es)
CN (1) CN109311972A (es)
AR (1) AR108790A1 (es)
AU (2) AU2016411388A1 (es)
BR (1) BR112018076287A2 (es)
CA (1) CA3020894A1 (es)
EA (1) EA201892707A1 (es)
MX (2) MX2018015363A (es)
TW (2) TW202327653A (es)
WO (1) WO2017217985A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3558369T1 (sl) 2016-12-21 2025-06-30 Cephalon Llc Protitelesa, ki se specifično vežejo na človeški il-15, in njihova uporaba
JP2022512709A (ja) * 2018-10-31 2022-02-07 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー 炎症性疾患及び自己免疫疾患を処置する組成物及び方法
CR20240130A (es) 2021-08-12 2024-04-12 Amgen Inc Formulaciones de anticuerpos
MA71681A (fr) 2022-08-04 2025-05-30 Novartis Pharma Ag Inhibiteurs d'il-15 utiles pour le traitement de la dermatite atopique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
RS20050724A (sr) * 2003-02-26 2007-11-15 Genmab A/S., Humana antitela specifična za interleukin 15(il-15)
PE20120586A1 (es) * 2009-01-29 2012-06-17 Abbott Lab Proteinas de union a il-1
WO2011031986A1 (en) * 2009-09-10 2011-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Assays for soluble il-15 receptor alpha
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15

Also Published As

Publication number Publication date
AR108790A1 (es) 2018-09-26
AU2024205264A1 (en) 2024-08-22
AU2016411388A1 (en) 2018-11-08
TW202327653A (zh) 2023-07-16
JP2022001577A (ja) 2022-01-06
EA201892707A1 (ru) 2019-05-31
CN109311972A (zh) 2019-02-05
TW201803591A (zh) 2018-02-01
BR112018076287A2 (pt) 2019-03-26
MX2024001374A (es) 2024-02-27
JP2019521981A (ja) 2019-08-08
EP3472202A1 (en) 2019-04-24
WO2017217985A1 (en) 2017-12-21
CA3020894A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
EP4378536A3 (en) Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP4620519A3 (en) Methods and compositions relating to chondrisomes from blood products
MD20170032A2 (ro) Anticorpi anti-TIGIT
NZ737399A (en) Ccr2 modulators
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
NZ723884A (en) Methods of treating alzheimer’s disease
MX2017002489A (es) Agentes terapeuticos humanos.
PH12017500602A1 (en) Methods for treating ocular conditions
ZA201807438B (en) Methods of treating ocular conditions
EA201791937A1 (ru) Противовоспалительные полипептиды
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
TW201713323A (en) Therapeutic compositions and methods of use thereof
MX2024001374A (es) Anticuerpo anti-il-15 o fragmento de union a antigeno del mismo, para usarse en el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.
JOP20190164B1 (ar) تركيبات وطرق لعلاج داء فاربر
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
EP4218789A3 (en) Compositions for colon cleansing and the treatment of gastrointestnal disorders
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
PH12017501979A1 (en) Pharmaceutical compound